Cytek Biosciences (CTKB) Change in Receivables (2020 - 2026)

Cytek Biosciences has reported Change in Receivables for 7 years, with the latest figure at -$9.6 million in Q1 2026.

• For the quarter ending Q1 2026, Change in Receivables fell 49.56% year-over-year to -$9.6 million; the trailing twelve-month figure through Mar 2026 stood at -$3.6 million (down 210.89% YoY), and the FY2025 full-year result was -$368000.0, down 106.78% from the prior year.
• Change in Receivables for Q1 2026 stood at -$9.6 million, down from $6.1 million in the prior quarter.
• The five-year high for Change in Receivables was $9.3 million in Q4 2024, with the low at -$9.6 million in Q1 2026.
• Historically, Change in Receivables has averaged $1.3 million across 5 years, with a median of $1.0 million in 2022.
• Annual changes were most pronounced in 2023 — Change in Receivables tumbled 683.33% — and 2024, when it jumped 3647.15%.
• Cytek Biosciences' Change in Receivables stood at $8.0 million in 2022, then plunged by 103.3% to -$263000.0 in 2023, then jumped by 3647.15% to $9.3 million in 2024, then tumbled by 34.12% to $6.1 million in 2025, then plunged by 256.93% to -$9.6 million in 2026.
• The last three Change in Receivables figures came in at -$9.6 million (Q1 2026), $6.1 million (Q4 2025), and $587000.0 (Q3 2025), per Business Quant data.